

DIVI'S LABORATORIES LIMITED

UNAUDITED FINANCIAL RESULTS (STANDALONE)
FOR THE QUARTER ENDED 30TH JUNE, 2011

(Rs.in Lakhs)

		STAND ALONE		
	Particulars	Quarter ended 30.06.2011	Quarter ended 30.06.2010	Year Ended 31.03.2011
		Unaudited	Unaudited	Audited
	(1)	(2)	(3)	(4)
1	Net Sales/Income from operations (Net of Excise Duty)	35855	26254	130544
	Other Operating Income	626	683	1247
	<u>Total Income:</u>	36481	26937	131791
2	<u>Expenditure:</u>			
	a. (Increase)/decrease in stock in trade and work in progress	(3626)	(1424)	3452
	b. Consumption of Raw Material	17908	11578	48668
	c. Purchase of Traded Goods	0	0	0
	d. Employees Cost	2447	1737	8049
	e. Depreciation	1400	1311	5335
	f. Other Expenditure			
	- Manufacturing Expenses	2994	2124	10207
	- Other expenses	3358	2671	10722
	g. Total	24481	17997	86433
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	12000	8940	45358
4	Other Income	1015	490	2613
5	Profit before Interest & Exceptional Items (3+4)	13015	9430	47971
6	Interest	22	22	66
7	<u>Profit after Interest but before Exceptional items (5-6)</u>	12993	9408	47905
8	Exceptional items	0	0	0
9	<u>Profit from ordinary activities before Tax (7-8)</u>	12993	9408	47905
10	Tax Expense			
	- Current Tax	2465	719	3920
	- MAT Credit Utilisation/Entitlements	260	(5)	128
	- Deferred Tax	9	65	300
11	<u>Net Profit from ordinary activities after Tax: (9-10)</u>	10259	8629	43557
12	Extra-ordinary items	0	0	0
13	Net Profit (+)/Loss(-) for the period (11-12)	10259	8629	43557

14	Paid-up Equity Share Capital (Face Value : Rs.2 per share)	2653	2643	2652
15	Reserves excluding revaluation reserves as per balance sheet of previous accounting year			180153
16	Earnings per Share:			
a)	Basic Earnings Per Share before extra-ordinary items Rs.	7.74	6.53	32.90
	Diluted Earnings Per Share before extra-ordinary items Rs.	7.73	6.52	32.88
b)	Basic Earnings Per Share after extra-ordinary items Rs.	7.74	6.53	32.90
	Diluted Earnings Per Share after extra-ordinary items Rs.	7.73	6.52	32.88
17	Public shareholding			
	- No. of shares	63427130	62959045	63372210
	- Percentage of shareholding	47.8 2%	47.64%	47.79%
18	Promoters and promoter group shareholding:			
	a) pledged / encumbered	Nil	Nil	Nil
	b) non-encumbered:			
	No. of shares	69222900	69185100	69222900
	Percentage of shares (as a % of the total shareholding of the promoter group)	100%	100%	100%
	Percentage of shares (as a % of the total share capital of the company)	52.18%	52.36%	52.21%

NOTES:

1. The above results for the quarter ended 30th June 2011, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 6th August, 2011 and were subjected to 'limited review' by the Auditors.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.
3. As per Clause 41 of the listing agreement, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.
4. Figures for the previous year/period have been regrouped or recasted, wherever necessary.
5. During the current quarter, the company has allotted 54,920 equity shares of Rs.2/- each to the employees on exercise of their stock options.
6. The "DSN SEZ Unit" at Visakhapatnam has commenced commercial operations from 1st June, 2011.
7. Details of Investor complaints pursuant to Clause 41 of the Listing Agreement for the quarter ended 30.06.2011:
Opening: Nil, Received during the Quarter: 4, Resolved: 4, Closing: Nil

for Divi's Laboratories Limited

Place: Hyderabad
Date: 6th August, 2011

Dr. Murali K. Divi
Chairman & Managing Director